Stock Analysis

KRX Growth Companies With High Insider Ownership Growing Earnings Up To 99%

Published

The South Korean market has remained flat over the past year, with the Utilities sector gaining 11% in the last week. In this environment, identifying growth companies with high insider ownership can be crucial as these stocks often indicate strong confidence from those closest to the business and potential for significant earnings growth.

Top 10 Growth Companies With High Insider Ownership In South Korea

NameInsider OwnershipEarnings Growth
People & Technology (KOSDAQ:A137400)16.5%35.6%
Seojin SystemLtd (KOSDAQ:A178320)30.9%52.1%
Bioneer (KOSDAQ:A064550)17.5%89.7%
Global Tax Free (KOSDAQ:A204620)20.9%78.5%
ALTEOGEN (KOSDAQ:A196170)26.6%99.5%
Oscotec (KOSDAQ:A039200)26.3%114.7%
Vuno (KOSDAQ:A338220)19.5%110.9%
HANA Micron (KOSDAQ:A067310)21.3%97.4%
UTI (KOSDAQ:A179900)33.1%122.7%
Techwing (KOSDAQ:A089030)18.7%77.8%

Click here to see the full list of 89 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

ZeusLtd (KOSDAQ:A079370)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Zeus Co., Ltd. (KOSDAQ: A079370) offers semiconductor, robot, and display total solutions in South Korea and internationally with a market cap of ₩458.74 billion.

Operations: Revenue segments include Valve with ₩23.67 billion and Equipment Division with ₩467.14 billion.

Insider Ownership: 33.3%

Earnings Growth Forecast: 44.2% p.a.

Zeus Ltd. has demonstrated significant growth, with second-quarter sales increasing to KRW 130.80 billion from KRW 95.13 billion a year ago and net income rising to KRW 6.79 million from a loss of KRW 1.76 million. The company’s earnings are forecast to grow at an impressive rate of 44.19% annually, outpacing the market average of 28.8%. Despite recent volatility in share price and past shareholder dilution, Zeus Ltd.'s revenue is expected to grow faster than the South Korean market at 15.4% per year.

KOSDAQ:A079370 Ownership Breakdown as at Aug 2024

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc., a bio company with a market cap of ₩16.60 billion, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

Operations: The company's revenue segment is primarily derived from Biotechnology, amounting to ₩90.79 million.

Insider Ownership: 26.6%

Earnings Growth Forecast: 99.5% p.a.

ALTEOGEN Inc. is forecast to become profitable within three years, with revenue expected to grow at 64.2% annually, significantly outpacing the South Korean market's average growth rate of 10.6%. Despite recent shareholder dilution and a highly volatile share price over the past three months, it trades at 75.7% below its estimated fair value. The recent MFDS approval of Tergase® marks a pivotal milestone as ALTEOGEN transitions into a commercial-stage company with promising product applications in various medical fields.

KOSDAQ:A196170 Ownership Breakdown as at Aug 2024

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. operates in music production, publishing, and artist development and management with a market cap of ₩7.38 trillion.

Operations: HYBE's revenue segments include Label with ₩1.28 trillion, Platform with ₩361.12 million, and Solution with ₩1.24 trillion.

Insider Ownership: 32.5%

Earnings Growth Forecast: 42.5% p.a.

HYBE Co., Ltd. has substantial insider ownership and is expected to see significant annual profit growth of 42.47% over the next three years, outpacing the South Korean market's average. Despite recent earnings showing a decline in net income from KRW 117,339 million to KRW 14,592.95 million year-over-year for Q2 2024 due to one-off items, it trades at 22.4% below its estimated fair value with analysts forecasting a potential stock price increase of 45.3%.

KOSE:A352820 Earnings and Revenue Growth as at Aug 2024

Make It Happen

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're here to simplify it.

Discover if HYBE might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com